Physician profile
Aaron Lin
NPI 1053706309
$766.60
in general payments reported to CMS, 2019-2025
15 companies · $61.99 in 2025
The $61.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $77.47 · 2022: $51.16 · 2023: $103 · 2024: $265 · 2025: $61.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $127.73 | 2023-2024 | |
| Novo Nordisk INC | $105.66 | 2019-2024 | Wegovy |
| Lilly USA, LLC | $104.26 | 2019-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $84.01 | 2019-2024 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $82.25 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $52.22 | 2019-2020 | |
| Esperion Therapeutics, INC. | $34.86 | 2024 | Nexletol |
| Amgen INC. | $33.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.86 | 2022-2023 | |
| Ibsa Pharma INC. | $22.84 | 2025 | Tirosint, Licart, Flector |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.46 | 2022 | |
| Allergan, INC. | $20.75 | 2020 | |
| Dynavax Technologies Corporation | $18.48 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.53 | 2024 | Voquezna |
| Linus Health, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.